Asahi Kasei obtains license regarding allogenic iPS cell-derived cartilage
October 17, 2018
Asahi Kasei Corp.
Asahi Kasei has concluded a license agreement with iPS Academia Japan, Inc. for iPS cell technology patented by Kyoto University.
The agreement grants Asahi Kasei a worldwide license for iPS cell-related patents licensed by iPS Academia Japan to treat traumatic articular cartilage damage1, non-exclusive for iPS cell technology and exclusive for technology to induce chondrification2. Under the terms of the agreement, Asahi Kasei obtains exclusive rights to develop, manufacture, and sell products of regenerative medicine derived from iPS cells for the treatment of traumatic articular cartilage damage.
iPS Academia Japan receives a lump sum payment and development milestones as well as royalties proportional to sales amounts and sales milestones.
Asahi Kasei will work to establish manufacturing technology to commercialize products of regenerative medicine derived from iPS cells for traumatic articular cartilage damage through collaborative research with Prof. Noriyuki Tsumaki of the Center for iPS Cell Research and Application at Kyoto University.
By adding regenerative medicine technology for cartilage to its R&D platform, Asahi Kasei intends to further strengthen business in the field of orthopedics.
https://www.asahi-kasei.co.jp/asahi/en/news/2018/e181017.html
https://www.asahi-kasei.co.jp/asahi/jp/news/2018/ze181017.html